They are.Sometimes they work against us. To avoid what you have experienced I started trading option spreads.They are a sort of stop loss
Yinvestor, you are correct.I have been rolling some call options since Tiny reached bottom.It is a very very small investment and I believe it will pay.I will stop rolling and take a minor loss if I see a change in trend in the chart
Why did you put all your savings in a single company? I am sure your parents taught you never to put all the eggs in one basket case. This is common sense 101 Turn you trade to a covered call in order to collect premiun and reduce your potential losses
EMC long trem investment is about 6 billlion and Goodwill about 12 billion.In those two accounts is included the VMW investment. These vaLues do not reflect the market value of vmw
Analysts at JP Morgan Cazenove raised their price target on shares of Sprint Nextel from $6.00 to $8.00 in a research note to investors on Tuesday. They now have an "overweight" rating on the stock
ladies use your time more productively, you remind me of Sopphie Loren in an Italian movie, fighting with other women in the food market. The exception is that she is quite a lady
If you have an account at Schwab you receive its email alerts or you can go to its site,log in look for the trade tap then research and you will find Schwab opinion as well as others
Guys, why do you keep holding this stock? When I am fed up with a company I sell the shares and walk away
Analysts at Zacks reiterated a "neutral" rating on shares of Zalicus in a research note to investors on Wednesday. They now have a $1.00 price target on the stock. Zacks' analyst wrote, " Zalicus Stock is starting to look very interesting at this level. The stock has been basing nicely between $0.60 and $0.80 as traders no doubt are waiting for the big phase 2 data on potential blockbuster drug Z160 coming in the fourth quarter 2013. But now might be the time value biotech investors take a look at the stock. The currently market capitalization is only $82 million. That's less than 5X our projected 2013 revenues of $17.0 million, and 45% of the market capitalization is supported by the cash balance. With Z160 a potential blockbuster and the top-line supporting the stock at today's price, Zalicus could be poised for a big second half of the year. Our rating is Neutral', but currently under-review."
Analysts at Oppenheimer reiterated an "outperform" rating on shares of Zalicus in a research note to investors on Wednesday. They now have a $2.00 price target on the stock. The analysts wrote, "Investors remain focused on the two ongoing Z160 Phase IIa proof-of-concept studies in chronic neuropathic pain. Zalicus now expects to report top-line data from these studies by late-2H13. As a reminder, the two Phase IIa studies include Lumbosacral Radiculopathy (LSR) and Postherpetic Neuralgia (PHN). Zalicus stated that it will continue the clinical development of Z944 in 2013. A key US patent was issued in February 2013 that provides coverage through April 2029. We believe that, with total cash of $36.4M at YE12, Zalicus is capitalized past data readout of its two Z160 Phase IIa studies and into 2014."